Physician profile
Fei Bao
NPI 1336475409
$1,669.50
in general payments reported to CMS, 2019-2025
17 companies · $285 in 2025
The $285 reported for 2025 was more than what 83% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $17.94 · 2021: $123 · 2022: $494 · 2023: $264 · 2024: $196 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $409.54 | 2019-2024 | Keytruda, Lynparza |
| Blueprint Medicines Corporation | $244.47 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $181.02 | 2025 | Daybue |
| Si-Bone, INC. | $132.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $118.81 | 2023 | Imfinzi |
| Lilly USA, LLC | $117.50 | 2022 | |
| Corcept Therapeutics | $103.80 | 2025 | Korlym |
| Daiichi Sankyo INC. | $52.39 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $43.13 | 2019 | |
| Genentech USA, INC. | $39.83 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $23.97 | 2019 | |
| Eisai INC. | $17.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2019 | |
| Genzyme Corporation | $15.47 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $14.21 | 2019 | |
| Janssen Biotech, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Bao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.